What Is Proteomics? Research Areas, Funding, and Career Paths

Proteomics is the large-scale study of the proteome — the complete set of proteins expressed by a cell, tissue, or organism at a given time, including how much of each protein is present, how it is chemically modified, how it is folded and structured, and how it interacts with other proteins. Where genetics and genomics describe an organism’s fixed genetic blueprint, the proteome is the dynamic, functional output of that blueprint: it changes from cell type to cell type, over developmental time, and in response to disease, drugs, and environment. A proteomics researcher’s basic question is almost always some version of: which proteins are present, in what quantity, in what modified form, and doing what — answered not one protein at a time, but across thousands of proteins simultaneously using high-throughput instrumentation, chiefly mass spectrometry.

What Proteomics Actually Studies

Modern proteomics covers several interlocking lines of inquiry:

• Protein identification and quantification — determining which proteins are present in a sample and measuring their relative or absolute abundance, often comparing conditions (healthy vs. diseased tissue, treated vs. untreated cells).
• Post-translational modifications (PTMs) — mapping chemical modifications added to proteins after synthesis (phosphorylation, glycosylation, ubiquitination, acetylation, and others) that switch protein activity on or off, mark proteins for degradation, or control localization.
• Protein structure — determining the three-dimensional shape of proteins and protein complexes, since structure determines function; this overlaps heavily with structural biology.
• Protein-protein interactions and complexes — mapping the “interactome,” the network of physical interactions that let proteins assemble into functional machines and signaling pathways.
• Differential and clinical proteomics — comparing proteomes between disease and healthy states, or before and after treatment, to identify candidate biomarkers or drug targets.

Because the human genome encodes roughly 20,000 protein-coding genes but alternative splicing, combinatorial PTMs, and proteolytic processing generate a far larger number of distinct protein forms (proteoforms), the proteome is substantially more complex than the genome that specifies it — and, unlike the genome, it is different in every cell type and constantly changing. That complexity, combined with the wide dynamic range of protein abundance in a biological sample, is what makes proteomics technically demanding and drives much of its methodological innovation.

How Proteomics Relates to Neighboring Disciplines

Proteomics sits at the intersection of several established fields rather than standing apart from them:

• Biochemistry studies the chemistry of individual molecules and pathways in depth — how one enzyme catalyzes one reaction, for example. Proteomics takes a systems-level, high-throughput approach, profiling thousands of proteins in a single experiment rather than studying one molecule at a time; in practice, proteomics grew out of and remains closely tied to protein biochemistry. See CASRAI’s guide to biochemistry for the molecule-by-molecule foundation proteomics builds on.
• Genomics studies the genome — the complete DNA sequence and its organization — while proteomics studies the functional output the genome specifies. The two fields are complementary parts of the “central dogma” pipeline (DNA to RNA to protein) and are increasingly studied together in integrated multi-omics projects that combine genomic and proteomic data on the same samples, such as NCI’s tumor-proteogenomics work described below. CASRAI’s companion guide on what genomics studies is part of this same discipline series (see the branches-of-science hub linked at the end of this page for the full, current list).
• Bioinformatics supplies the computational backbone proteomics depends on: matching raw mass spectrometry spectra to peptide sequences, controlling false-discovery rates across millions of candidate matches, and integrating protein data with genomic, transcriptomic, and pathway databases. A modern proteomics experiment generates far more raw data than any researcher could interpret by hand, which is why proteomics and bioinformatics are practiced as tightly coupled disciplines. See CASRAI’s guide to bioinformatics for the computational methods proteomics relies on.
• Molecular biology and cell biology provide the biological context — gene expression, cell signaling, organelle structure — that proteomic data is interpreted against; proteomics is often described as one experimental layer within a broader molecular/cell-biology research program rather than a fully separate discipline.

Major Subfields Within Proteomics

Proteomics researchers typically specialize by technique, biological question, or scale:

• Expression (quantitative) proteomics — measuring how protein abundance changes between conditions, using label-free quantification or isotope/isobaric labeling strategies (SILAC, TMT, iTRAQ).
• Structural proteomics — solving the three-dimensional structures of proteins and complexes, overlapping with structural biology methods such as X-ray crystallography, cryo-electron microscopy, and NMR.
• Functional / interaction proteomics — mapping protein-protein interaction networks and multi-protein complexes, often via affinity purification coupled to mass spectrometry.
• PTM-focused proteomics — specialized subfields such as phosphoproteomics, glycoproteomics, and ubiquitinomics that enrich for and characterize a specific class of protein modification.
• Top-down vs. bottom-up proteomics — bottom-up (the dominant approach) digests proteins into peptides before mass spectrometry analysis and reconstructs protein identity computationally; top-down analyzes intact proteins directly, preserving information about proteoforms that bottom-up methods can lose.
• Clinical and translational proteomics — applying proteomic profiling to human disease, most prominently in oncology (tumor proteogenomics) but increasingly in neurodegenerative disease biomarker discovery, connecting proteomics to neurobiology, and in psychiatric-illness biomarker research, connecting it to psychiatry.
• Single-cell and spatial proteomics — an actively developing subfield extending proteomic profiling down to individual cells or preserving spatial location within tissue, analogous to the single-cell and spatial methods already reshaping genomics and transcriptomics.

Who Funds Proteomics Research

This is the piece a general encyclopedia entry on proteomics typically skips, and it matters if you are trying to understand the field as a research enterprise rather than only as a body of scientific knowledge. In the United States, proteomics research is funded through several federal routes, split roughly between basic-methods funding and disease-application funding:

• The National Institutes of Health (NIH) — the National Institute of General Medical Sciences (NIGMS) is NIH’s primary funder of basic, non-disease-targeted biomedical research, and fundamental proteomic technology and methods development falls squarely within its scope, alongside biochemistry and molecular biology more broadly. Disease-specific proteomics is instead funded through the relevant NIH institute for that disease. The clearest example is the National Cancer Institute (NCI), which runs the Clinical Proteomic Tumor Analysis Consortium (CPTAC) through its Office of Cancer Clinical Proteomics Research — a major national program that pairs genomic and proteomic characterization of the same tumor samples (“proteogenomics”) to find cancer drug targets and biomarkers, and remains an active program as of 2026. Other institutes, such as the National Heart, Lung, and Blood Institute (NHLBI), have similarly funded proteomics centers focused on cardiovascular, pulmonary, and blood-disease proteins, and institutes with a neurodegenerative or psychiatric disease mission fund proteomic biomarker studies within their own disease scope.
• The National Science Foundation (NSF) — within NSF’s Directorate for Biological Sciences (BIO), the Division of Molecular and Cellular Biosciences (MCB) is the primary home for fundamental, non-biomedical proteomics and protein-science research. NSF’s Major Research Instrumentation (MRI) program is also a common funding route specifically for the mass spectrometers and other high-cost instrumentation a proteomics lab or core facility needs, rather than for research questions themselves.
• Private foundations play a smaller but real role. The Chan Zuckerberg Initiative (CZI) has run a “Visual Proteomics” funding cycle as part of its broader imaging and Human Cell Atlas-adjacent science programs, alongside its other imaging and open-source-software RFAs — treat specific cycle amounts as time-sensitive and verify current scope directly against CZI’s own site before citing a dollar figure. No proteomics-exclusive major foundation funder is well established the way, for example, disease-specific foundations exist in other fields; most private funding proteomics researchers receive comes through foundations organized around a disease or a broader life-science technology mission rather than around proteomics as a method.

None of this is an exhaustive funding directory — program names, paylines, and eligibility rules change, and a researcher planning an actual application should verify current program scope directly against NIGMS’s, NCI’s, NSF MCB’s, or the relevant foundation’s own current guidance rather than treating this summary as current as of application date.

Typical Research Methods, Tools, and Equipment

A proteomics lab’s toolkit is built around separating, identifying, and quantifying proteins at scale:

• Mass spectrometry (MS) — the dominant technology in modern proteomics, typically coupled to liquid chromatography (LC-MS) to separate peptides before they enter the mass spectrometer. CASRAI’s own LC-MS guide and proteomics mass spectrometry guide cover the instrument choices, acquisition strategies (data-dependent vs. data-independent acquisition, DDA vs. DIA), and sample-prep decisions in practical detail.
• Protein/peptide separation and sample prep — gel electrophoresis (including two-dimensional gels, historically foundational to the field), column chromatography, and increasingly automated sample-preparation workflows that reduce the hands-on variability large proteomics studies are sensitive to.
• Quantitative labeling strategies — isotope labeling approaches such as SILAC (metabolic labeling in cell culture) and isobaric tags such as TMT and iTRAQ, which allow several samples to be quantitatively compared within a single mass spectrometry run.
• Database search and identification software — computational tools (such as MaxQuant, Mascot, and similar peptide/protein identification engines) that match observed mass spectra against predicted spectra from a reference protein sequence database, with statistical false-discovery-rate control applied across the very large number of candidate matches a single run produces.
• Data repositories and standards — proteomics datasets are commonly deposited through the ProteomeXchange consortium, which CASRAI covers in its own branches-of-science companion content; UniProt, covered in CASRAI’s UniProt guide, is the standard reference protein sequence and functional-annotation database the field searches against.
• Immunoassays and targeted methods — western blotting, ELISA, and targeted mass spectrometry methods (multiple/selected reaction monitoring, MRM/SRM) for validating specific proteins identified in a discovery-scale experiment, rather than profiling the whole proteome.

Career and Training Pathways

Most independent proteomics researchers hold a PhD, typically in biochemistry, molecular biology, analytical or biological chemistry, or an interdisciplinary “quantitative biology”/biomedical sciences program with a proteomics or mass spectrometry concentration. A typical path is an undergraduate degree in chemistry, biochemistry, or biology, followed by a PhD program of roughly five to six years that includes coursework, laboratory rotations, a qualifying exam, and a dissertation built around a mass spectrometry-based or computational proteomics project. Many proteomics PhDs then complete a postdoctoral position, often two to five years, before moving into an independent academic role, a core-facility or shared-instrumentation leadership position, or an industry role in biotechnology, pharmaceutical development, or diagnostics. Because proteomics is fundamentally instrument- and data-intensive, technician and staff-scientist roles running mass spectrometry core facilities are a distinct, accessible career track for people with a bachelor’s or master’s degree plus specialized instrument training, rather than requiring a PhD.

The Human Proteome Organization (HUPO) is the main international scientific organization for the field, coordinating global initiatives such as the Human Proteome Project and holding an annual World Congress that brings the discipline together across its many subfields. The American Society for Mass Spectrometry (ASMS) is the principal professional society on the analytical/instrumentation side that many proteomics researchers also belong to, since mass spectrometry is the field’s core technology rather than an occasional tool. Researchers moving between proteomics and its closest neighbors also frequently belong to societies anchored in those adjacent fields, such as the American Society for Biochemistry and Molecular Biology, depending on their specific research focus.

Frequently Asked Questions

What is the difference between proteomics and genomics?

Genomics studies the genome — an organism’s essentially fixed DNA sequence — while proteomics studies the proteome, the set of proteins that genome actually produces, which varies by cell type, changes constantly, and is shaped by alternative splicing and chemical modification in ways the genome sequence alone doesn’t capture. The two fields are increasingly combined in “proteogenomic” studies that analyze both layers on the same samples.

What is the difference between proteomics and biochemistry?

Biochemistry traditionally studies one molecule or pathway at a time in mechanistic depth; proteomics takes a large-scale, high-throughput approach, profiling thousands of proteins simultaneously using mass spectrometry. Proteomics grew directly out of protein biochemistry and the two fields share methods, journals, and often academic departments.

Do you need a PhD to work in proteomics?

Independent, principal-investigator-level proteomics research almost always requires a PhD. A meaningful amount of proteomics-adjacent laboratory work — running and maintaining mass spectrometry instrumentation in a core facility, sample preparation, and technical support roles — is accessible with a bachelor’s or master’s degree plus specialized instrument training, working under PhD-level scientific direction.

What jobs can you get with a proteomics background?

With a bachelor’s or master’s degree: mass spectrometry core-facility technician, quality control roles in biotech and pharmaceutical manufacturing, and research support positions. With a PhD: independent academic research, industry research and development in biotech, pharma, and diagnostics (including biomarker and drug-target discovery), core-facility leadership, and, via additional training or transition, science policy, regulatory affairs, and research administration.

Where Proteomics Fits Among the Sciences

For a broader map of how proteomics relates to the full set of major scientific disciplines — from biochemistry and genomics through to fields well outside the life sciences — see CASRAI’s overview guide to the branches of science, which organizes every published discipline guide by category (Physical Sciences, Life Sciences, Formal Sciences, Social Sciences, and Applied Sciences & Engineering) and which this page is part of a companion series alongside.